MRK
HealthcareMerck & Co.
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2007–2025(19yr)| Metric | FY 2007 | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.2B | $23.9B | $27.4B | $46.0B | $48.0B | $47.3B | $44.0B | $42.2B | $39.5B | $39.8B | $40.1B | $42.3B | $46.8B | $48.0B | $48.7B | $59.3B | $60.1B | $64.2B | $65.0B | +1.3% |
| Gross Profit | $18.1B | $18.3B | $18.4B | $27.6B | $31.2B | $30.8B | $27.1B | $25.5B | $24.6B | $25.8B | $27.2B | $28.8B | $32.7B | $32.5B | $35.1B | $41.9B | $44.0B | $49.0B | $48.6B | -0.7% |
| Gross Margin | 74.6% | 76.6% | 67.1% | 60.0% | 64.9% | 65.2% | 61.5% | 60.3% | 62.2% | 64.8% | 67.8% | 68.1% | 69.9% | 67.7% | 72.0% | 70.6% | 73.2% | 76.3% | 74.8% | -1.5pp |
| Net Income | $3.3B | $7.8B | $12.9B | $861.0M | $6.3B | $6.2B | $4.4B | $11.9B | $4.4B | $3.9B | $2.4B | $6.2B | $9.8B | $7.1B | $13.0B | $14.5B | $365.0M | $17.1B | $18.3B | +6.6% |
| Net Margin | 13.5% | 32.7% | 47.0% | 1.9% | 13.1% | 13.0% | 10.0% | 28.2% | 11.2% | 9.8% | 6.0% | 14.7% | 21.0% | 14.7% | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% | +1.4pp |
| Free Cash Flow | $6.0B | $5.3B | $1.9B | $9.1B | $10.7B | $8.1B | $10.1B | $6.5B | $11.1B | $8.8B | $4.6B | $8.3B | $10.0B | $5.6B | — | $14.7B | $9.1B | $18.1B | $12.4B | -31.7% |
| FCF Margin | 24.7% | 22.1% | 7.0% | 19.9% | 22.2% | 17.1% | 23.0% | 15.5% | 28.2% | 22.0% | 11.4% | 19.6% | 21.3% | 11.6% | — | 24.8% | 15.2% | 28.2% | 19.0% | -9.2pp |
| EPS (Diluted) | $1.49 | $3.63 | $5.65 | $0.28 | $2.02 | $2.00 | $1.47 | $4.07 | $1.56 | $1.41 | $0.87 | $2.32 | $3.81 | $2.78 | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 | +8.0% |
1. THE BIG PICTURE
Merck & Co. is currently defined by a precarious "Keytruda paradox": the drug is the engine of its industry-leading margins, yet its sheer dominance creates a dangerous single-point-of-failure for the business. As Merck & Co. approaches a major patent cliff, its survival as a growth entity depends entirely on whether its aggressive acquisition strategy can replace nearly half of its revenue base before generic competition and government price-setting take hold.
2. WHERE THE RISKS HIT HARDEST
Merck & Co.’s primary strength in oncology is threatened by Patent Exclusivity Loss because Keytruda alone represented 49% of total sales in 2025 (Risks). Any entry of biosimilars would result in a "rapid and significant loss of sales" for Merck & Co.'s most vital cash generator.
Merck & Co.’s established vaccine franchise is threatened by Geographic Concentration Risk in China. While Gardasil has historically been a pillar of the Pharmaceutical segment, sales plummeted 34% in the fourth quarter of 2025 due to an inventory pause by a Chinese commercialization partner, with management warning that no material increase is expected in 2026 (Recent Results).
Finally, Merck & Co.’s R&DR&DResearch & Development — spending on creating new products or technologies-led competitive advantage is threatened by Government Price Setting under the Inflation Reduction Act. The U.S. government has already targeted Januvia and Lenvima for price negotiations, with Keytruda expected to follow, which will likely cause material declines in profit margins regardless of how much Merck & Co. invests in "breakthrough science" (10-K Item 1).
3. WHAT THE NUMBERS SAY TOGETHER
(XBRL) The financial data reveals a company that is exceptionally efficient but fundamentally stalling. Merck & Co. maintains the highest net margin in its peer group at 28.3%, yet it reported the slowest revenue growth at just 1.3%. This suggests that while Merck & Co. is a "cash cow," it is struggling to find new top-line momentum. The fourth quarter of 2025 highlighted this tension: while sales grew 5%, GAAPGAAPGenerally Accepted Accounting Principles — the standard U.S. accounting rules all public companies must follow net income fell 21% to $2.96 billion, largely due to a $3.65 per share charge related to the acquisition of Cidara Therapeutics (8-K).
The growth trajectory is currently bifurcated. While legacy blockbusters like Gardasil are declining, new launches in the cardiometabolic and respiratory space are showing triple-digit momentum, specifically Winrevair, which saw sales increase 133% to $467 million in the most recent quarter. This shift confirms that the "portfolio transformation" cited by management is active, but these new contributors are not yet large enough to offset the volatility in the core vaccine and oncology segments.
4. IS IT WORTH IT AT THIS PRICE?
At a 12.0x forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Merck & Co. trades at a 26% discount to the peer median of 16.1x. This makes it the cheapest stock in its immediate peer group. (CAPM analysis) The market is currently pricing in a long-term growth rate of only 0.5%.
This steep discount appears justified by Merck & Co.'s extreme revenue concentration. Investors are essentially paying a low multiple for current cash flows—supported by a peer-leading 1.5% buyback yield and a 2.9% dividend yield—while discounting the terminal value of the business due to the Keytruda patent cliff. If Merck & Co. can successfully navigate its pipeline and achieve even a modest GDP-paced growth of 2.5%, the justified multiple would rise to 29.0x. However, the immediate threat of government price-setting on Januvia and Keytruda remains the primary factor keeping the valuation suppressed.
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if Winrevair and Capvaxive sales continue to exceed quarterly estimates, proving that the new cardiometabolic and vaccine portfolios can successfully replace lost revenue from Januvia and Gardasil.
- Cautious if the "pause" in China shipments for Gardasil extends beyond 2026 or if Merck & Co. records further multi-billion dollar impairment charges related to its recent acquisitions of Verona Pharma or Cidara.
6. BOTTOM LINE
Structural Advantage: A high-margin oncology monopoly coupled with a diversified Animal Health segment that provides stable, digitally-integrated cash flows.
Bottom Line: Merck & Co. is a high-yield value play for investors who believe management can acquire its way out of a massive 2028 patent cliff.
1. Top 5 Material Risks
- Patent Exclusivity Loss: Merck & Co. relies on patent rights to maintain market exclusivity; the expiration of these rights typically leads to a rapid and significant loss of sales as generic or biosimilar versions enter the market.
- Product Concentration: A significant portion of profits and cash flows is generated by a small number of products, specifically Keytruda, Gardasil/Gardasil 9, Lynparza, Winrevair, and Bravecto.
- Government Price Setting: The U.S. government’s selection of products for price setting under the IRA—including Januvia, Janumet, Janumet XR, Lenvima, and eventually Keytruda—is expected to cause material declines in sales.
- Research and Development Failure: Merck & Co. must continuously launch new products to replace those losing patent protection, but the R&DR&DResearch & Development — spending on creating new products or technologies process is long, expensive, and carries a high risk of failure at any stage.
- Manufacturing and Supply Chain Disruptions: Merck & Co. faces risks of manufacturing delays, shortages, or quality assurance failures, particularly for complex biologics and vaccines, which can lead to lost sales and reputational harm.
2. Company-Specific Risks
- China Market Decline: Sales of Gardasil/Gardasil 9 in China declined significantly in 2025 due to a pause in shipments caused by high inventory levels at a commercialization partner, with no material increase expected in 2026.
- Animal Health Vulnerability: The Bravecto family of products accounted for 18% of the Animal Health segment’s sales in 2025, making the segment sensitive to any negative events affecting that specific product line.
- Self-Insurance Exposure: Merck & Co. self-insures substantially all of its product liability risk because commercial insurance is either cost-prohibitive or unavailable, leaving Merck & Co. directly exposed to the financial impact of product liability claims.
- Tax Contingency Risks: Merck & Co. is currently under examination by the IRS for tax years 2017, 2018, 2021, and 2022, including challenges to the one-time transition tax from the 2017 Tax Cuts and Jobs Act, which could result in material liabilities.
3. Regulatory/Legal Risks
- Medicare/Medicaid Rebates: The American Rescue Plan Act eliminated the statutory cap on Medicaid rebates, creating a risk where manufacturer discounts paid to state programs could exceed 100% of the Average Manufacturer Price.
- 340B Drug Discount Program: Increased utilization of the 340B Federal Drug Discount Program and limitations on Merck & Co.’s ability to identify inappropriate discounts are negatively impacting financial performance.
- International Pricing Controls: In Japan, the government mandates annual price reductions and can order re-pricing if product usage exceeds defined thresholds; in China, the Volume-Based Procurement (VBP) program has led to average price reductions of more than 50% for mature products.
- Sustainability Reporting: Evolving regulatory requirements, such as the EU’s Corporate Sustainability Reporting Directive (CSRD), increase compliance costs and expose Merck & Co. to potential government enforcement actions or private litigation.
4. Financial Impact Map
Patent Exclusivity Loss → Net Sales → Significant and rapid decline in revenue upon generic/biosimilar entry. Product Concentration (Keytruda) → Net Sales → 49% of total 2025 sales are derived from this single product. Government Price Setting (IRA) → Net Sales → Material decline in U.S. sales expected for Keytruda after 2029. R&DR&DResearch & Development — spending on creating new products or technologies Failure → Operating Expenses / Assets → Potential for material non-cash impairment charges for capitalized pipeline programs. Manufacturing Disruptions → Net Sales / Inventory → Potential for inventory write-downs and lost sales due to supply shortages.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-K | Feb 2026 | Dec 2025 |
| 8-K | Feb 2026 | — |
| 10-Q | Nov 2025 | Sep 2025 |
| 14A | Apr 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Merck Phase 3 Trial Shows Oral PCSK9 Inhibitor Reduces LDL-C by 64.6%
- ▸Enlicitide decanoate reduced LDL-C by 64.6% from baseline in Phase 3 trial
- ▸78.2% of patients achieved LDL-C goal of less than 55 mg/dL
- ▸Enlicitide demonstrated statistically significant reductions in apolipoprotein B and non-HDL cholesterol
- ▸Safety profile consistent with previous trials with no serious adverse events reported
- ▸Acquired Terns Pharmaceuticals for $6.7 billion to expand oncology and hematology portfolio
TuHURA Biosciences reports FY2025 results, updates Phase 3 IFx-2.0 enrollment timeline to mid-2027
- ▸Phase 3 IFx-2.0 trial enrollment expected to complete mid-2027
- ▸Appointed Craig Tendler, M.D. to oversee clinical development strategy
- ▸Acquired Kineta and TBS-2025 VISTA inhibiting antibody rights for $10.5 million
- ▸Raised $21.2 million in gross proceeds during fiscal year 2025
- ▸IFx-2.0 Phase 3 trial conducted under FDA Special Protocol Assessment agreement
TuHURA Biosciences Q4/FY2025 Results, IFx-2.0 Phase 3 Enrollment Expected Mid-2027
- ▸IFx-2.0 Phase 3 Merkel Cell Carcinoma trial enrollment expected mid-2027
- ▸Appointed Dr. Craig Tendler to oversee clinical development strategy
- ▸Acquired Kineta and TBS-2025 VISTA inhibiting antibody rights for $10.5 million
- ▸Raised $21.2 million in gross proceeds via direct offerings and private placements
- ▸IFx-2.0 Phase 3 trial conducted under FDA Special Protocol Assessment agreement
Merck to acquire Terns Pharmaceuticals for $6.7 billion in all-cash deal
- ▸Acquisition price $53.00 per share in cash
- ▸Total equity value approximately $6.7 billion
- ▸Net value $5.7 billion after accounting for acquired cash
- ▸Premium of 31% to 60-day volume-weighted average price
- ▸Adds TERN-701 chronic myeloid leukemia candidate to oncology portfolio
Merck enters $838M R&D collaboration with Infinimmune for antibody discovery
- ▸R&D collaboration deal valued at up to $838 million
- ▸Focus on discovering immune cell-directed antibodies for multiple targets
- ▸Partnership leverages Infinimmune's antibody discovery platform
- ▸Collaboration targets novel therapeutic development for Merck pipeline
Merck to acquire Terns Pharmaceuticals for $6.7B to bolster oncology pipeline
- ▸Acquiring Terns Pharmaceuticals for $6.7 billion cash
- ▸Lead asset TERN-701 targets chronic myelocytic leukaemia (CML)
- ▸TERN-701 Phase I/II trial showed 75% MMR rate vs 25.5% for Novartis's Scemblix
- ▸TERN-701 received FDA fast track designation in December 2025
- ▸Strategic move to diversify oncology portfolio ahead of Keytruda patent expiration
Merck WINREVAIR Phase 2 CADENCE trial meets primary endpoint in heart failure study
- ▸WINREVAIR significantly reduced pulmonary vascular resistance in CpcPH-HFpEF patients
- ▸Safety profile consistent with pulmonary arterial hypertension usage
- ▸Positive trends observed in six-minute walk distance and cardiac pressure measures
- ▸Merck projects $72B revenue and $24.3B earnings by 2028
- ▸Acquisition of Terns Pharmaceuticals valued at approximately $6.7 billion
Merck Q4 Revenue $16.4B Beats Estimates, FY Revenue Guidance $65.5B–$67B Misses Expectations
- ▸Q4 revenue $16.4B, beat analyst estimates of $16.2B
- ▸Q4 adjusted EPS $2.04, beat analyst estimates of $2.01
- ▸FY revenue guidance $65.5B–$67B, below analyst expectations
- ▸Licensed HS-10535 weight loss drug from Hanosh Pharmaceutical for $2B
- ▸Revenue impacted by loss of exclusivity for several medicines
Merck to acquire Terns Pharma for $6.7 billion to bolster cancer pipeline
- ▸Acquisition price $6.7 billion, representing 6% premium at $53 per share
- ▸Deal provides access to TERN-701, experimental chronic myeloid leukemia treatment
- ▸Transaction expected to close by Q2 2026
- ▸Strategic move to offset looming patent loss for blockbuster therapy Keytruda
- ▸Merck shares rose 5.5% following the announcement
Merck to Acquire Terns Pharmaceuticals for $6.7B, Targeting CML Market with TERN-701
- ▸Acquisition valued at $6.7 billion to bolster oncology and hematology pipeline
- ▸Lead asset TERN-701 is an allosteric TKI targeting chronic myeloid leukemia
- ▸Phase 1/2 CARDINAL study shows promising MMR and DMR rates at week 24
- ▸Merck targets over $70 billion in non-risk-adjusted commercial opportunity by mid-2030s
- ▸TERN-701 designed to overcome resistance mutations and improve therapeutic index over existing TKIs